Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 7, 2014, Pages 1061-1068

  Schmitz Dräger, Bernd J ^a,b   Todenhöfer, Tilman ^c   van Rhijn, Bas ^d   Pesch, Beate ^e   Hudson, Mĺiss A ^f   Chandra, Ashish ^g   Ingersoll, Molly A ^h   Kassouf, Wassim ⁱ   Palou, Joan ^j   Taylor, John ^k   Vlahou, Antonia ^l   Behrens, Thomas ^e   Critelli, Rossana ^m,n   Grossman, H Barton ^o   Sanchez Carbayo, Marta ^p   Kamat, Ashish ^o  

^a Urologie24   (Germany)

^b Center for Spinal Surgery   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f OCHSNER CLINIC FOUNDATION   (United States)

^g ST THOMAS HOSPITAL   (United Kingdom)

^h INSTITUT PASTEUR   (France)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j FUNDACIÓ PUIGVERT   (Spain)

^k UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^l Academy of Athens Biomedical Research Foundation   (Greece)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ Human Genetics Foundation   (Italy)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p CIC BIOGUNE   (Spain)

more..

Author keywords

Costs; Disease management; Low risk; Non muscle invasive bladder cancer; Urine markers

Indexed keywords

MOLECULAR MARKER; NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER;

AREA UNDER THE CURVE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; CYSTOSCOPY; FOLLOW UP; HEMATURIA; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; LUNG CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK FACTOR; TUMOR GROWTH; URINALYSIS; URINE CYTOLOGY; BLADDER TUMOR; URINE;

HUMANS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84920531742     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.10.010     Document Type: Review

References (38)

1. Schmitz-Dräger BJ, Droller M, Lotan Y, Lokeshwar VB, van Rhijn B, Hemstreet GP, et al. Molecular markers for bladder cancer screening, early diagnosis and surveillance. In: Soloway M, Khoury S, editors. Bladder Cancer: 2nd International Consultation on Bladder Tumors. Paris, France: Editions 2012; 21:171-205.
2. Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, et al. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int 2011;108:546-552.
3. Pressler JB, Bayer F, Dixon-Ernst C, Schmitz-Dräger BJ. Screening for bladder cancer using immunocytology-preliminary results from a prospective study in a professionally exposed cohort: the CTP project. 9th Meeting of the International Bladder Cancer Network, Madrid, Spain; 2011.
4. Vickers A.J., Bennette C., Kibel A.S., Black A., Izmirlian G., Stephenson A.J., et al. Who should be included in a clinical trial of screening for bladder cancer? a decision analysis of data from the prostate, lung, colorectal and ovarian cancer screening trial. Cancer 2013, 119:143-149.
5. Cha E.K., Tirsar L.-A., Schwentner C., Christos P.J., Mian C., Hennenlotter J., et al. Immunocytology is a strong predictor of bladder cancer presence in patients with asymptomatic hematuria: a multicenter study. Eur Urol 2012, 61:185-192.
6. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49. 466-465.
7. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, et al. Non muscle invasive bladder cancer. EAU Guidelines; 2013.
8. Mowatt G., Zhu S., Kilonzo M., Boachie C., Fraser C., Griffiths T.R., et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010, 14:1-331.
9. van der Aa M.N., Steyerberg E.W., Bangma C., van Rhijn B.W., Zwarthoff E.C., van der Kwast T.H. Cystoscopy revisited as the gold standard for detection of bladder cancer recurrences: diagnostic review bias in a randomised prospective trial (cefub-trial). J Urol 2010, 183:76-80.
10. van der Aa M.N., Zwarthoff E.C., Steyerberg E.W., et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol 2009, 55:659-668.
11. van Rhijn B.W., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance. A systematic review. Eur Urol 2005, 47:736-748.
12. van Rhijn B.W.G., Lurkin I., Kirkels W.J., van der Kwast T.H., Zwarthoff E.C. Microsatellite analysis: DNA-test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma. A phase II trial. Cancer 2001, 92:768-775.
13. Kamat A.M., Karam J.A., Grossman H.B., Kader A.K., Munsell M., Dinney C.P. Prospective trial to identify optimal bladder cancer surveillance protocol. BJU Int 2011, 108:1119-1123.
14. Yoder B.J., Skacel M., Hedgepeth R., et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007, 127:295-301.
15. Lotan Y., Bensalah K., Ruddell T., et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008, 179:2164-2169.
16. Becker N., Motsch E., Gross M.L., Eigentopf A., Heussel C.P., Dienemann H., et al. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. J Cancer Res Clin Oncol 2012, 138:1475-1486.
17. Son S.M., Choi S.Y., Lee H.C., Lee Y.M., Song H.G., Hwang H.K., et al. Evaluation of urine cytology in urothelial carcinoma patients: a comparison of CellprepPlus liquid-based cytology and conventional smear. Korean J Urol 2012, 46:68-74.
18. Xin W.R.S., Michael C.W. Low-grade urothelial carcinoma: reappraisal of the cytologic criteria on ThinPrep. Diagn Cytopathol 2003, 29(3):125-129.
19. Owens Christopher L.V., Burroughs F.H., Rosenthal D.L. A review of reporting systems and terminology for urine cytology. Cancer Cytopathol 2013, 121:19-24.
20. Mokhtar Ghadeer A., Al-Ghamedi D. Diagnostic significance of atypical category in the voided urine samples: a retrospective study in a tertiary care center. Urol Ann 2010, 2:100-106.
21. Vandenbussche C.J., Owens C.L., Burroughs F.H., Rosenthal D.L., Guan H. The Johns Hopkins Hospital template for urologic cytology samples: parts II and III-improving the prectability of indeterminate results in urinary cytologic samples: an outcomes and cytomorphologic study. Cancer Cytopathol 2013, 121:21-28.
22. Whisnant R.E., Ohori N.P. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification. Diagn Cytopathol 2003, 28:186-190.
23. Strittmatter F., Buchner A., Karl A., et al. Individual learning curve reduces the clinical value of urinary cytology. Clin Genitourin Cancer 2011, 9:22-26.
24. Reid M.D., Siddiqui M.T., Looney S.W. Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. Int J Clin Exp Pathol 2012, 5:882-891.
25. Yafi F.A., Brimo F., Auger M., Aprikian A., Tanguay S., Kassouf W. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urol Oncol 2013, Epub ahead of print.
26. Raab S.S., Grzybicki D.M., Vrbin C.M., Geisinger K.R. Urine cytology discrepancies: frequency, causes, and outcomes. Am J Clin Pathol 2007, 127:946-953.
27. Murphy William M., Soloway M.S., Jukkola A.F., Crabtree William N., Ford Kimball S. Urinary cytology and bladder cancer. Cancer 1984, 53:1555-1565.
28. Jackson J., Barkan G.A., Kapur U., Wojcik E.M. Cytologic and cystoscopic predictors of recurrence and progression in patients with low-grade urothelial carcinoma. Cancer Cytopathol 2013, 121:398-402.
29. The influence of urine cytology on our practice. Urol Ann 2012, 4:80-83. Alameddine MNA.
30. Huber S., Schwentner C., Taeger D., Pesch B., Nasterlack M., Leng G., et al. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int 2012, 110:699-708.
31. Oge O., Kozaci D., Gemalmaz H. The BTA stat test is nonspecific for hematuria: an experimental hematuria model. J Urol 2002, 167:1318-1319.
32. Horstmann M, Patschan O., Hennenlotter J., et al. Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 2009, 43:461-466.
33. Bravaccini S., Casadio V., Gunelli R., et al. Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. Ann Oncol 2011, 22:2294-2298.
34. Wild P.J., Fuchs T., Stoehr R., et al. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. Cancer Epidemiol Biomarkers Prev 2009, 18:1798-1806.
35. Todenhöfer T., Hennenlotter J., Esser M., Mohrhardt S., Tews V., Aufderklamm S., et al. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol 2013, 121:252-260.
36. Chamie K., Saigal C.S., Lai J., Hanley J.M., Setodji C.M., Konety B.R., et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011, 117:5392-5401.
37. de Bekker-Grob E.W., van der Aa M.N., Zwarthoff E.C., Eijkemans M.J., van Rhijn B.W., van der Kwast T.H., et al. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?. BJU Int 2009, 104:41-47.
38. Kamat A.M., Karam J.A., Grossman H.B., Kader A.K., Munsell M., Dinney C.P. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 2011, 108:1119-1123.